׳¦׳׳˜

הידעת? הדפדפן שהינך גולש ממנו אינו עדכני

הדפדפן שהינך גולש ממנו אינו עדכני ויתכן שהאתר אינו יעבוד בצורה טובה. הדפדפנים הנתמכים באתר הם:

לחץ על האיקונים למעבר לדף ההורדה של הדפדפן

סגירת חלונית אל תציג בשנית

בסגירת החלונית תועבר/י לאתר מותאם לדפדפן ויתכן כי חלק מהאתר לא יעבוד בצורה מיטבית

Dry Eye

הדפסה דוא

CDR - Center for Drug Repurposing

 

Dry eye disease is a multifactorial disease of the tears and eye surface that can result in ocular discomfort, corneal injury and visual impairment. Dry eye is also known as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome.

Worldwide, the prevalence of dry eye is estimated at between 15 – 30% of the population. It is more prevalent in the elderly and affects women more frequently than men. Dry eye is a common feature in diabetic patients.

 

Existing Treatment

The only FDA approved treatment for dry eye is Restasis® (cyclosporine) which works for 15% of users vs. 5% for whom placebo works. People suffering from dry eye are reliant on constant use of lubrication drops. Despite dozens of studies showing success of proposed treatments in animal models of dry eye, these have not translated into effective treatments for humans. The animal-models do not accurately correlate with either the course or multiple causes of human dry eye disease.

 

New Treatment

The Center for Drug Repurposing is researching a number of existing drugs for the new use of treating dry eye disease. In contrast to all other research, these treatments have already been tried in humans thanks to them being variation of use of existing FDA- approved drugs. These candidates are selected for their excellent safety profile, and include:

Dipyridamole (Persantin) is a drug that was originally introduced in 1959 as an anti-anginal medication and was subsequently found to inhibit platelet aggregation. It has a long history of safe usage. Long-term high-dose studies in mice have demonstrated that it is non-carcinogenic and non-mutagenic. The typical oral daily dose in humans ranges between 200 mg and 400 mg.

Following successful outcomes of patients treated with ultra-low-dose dipyridamole eye drops for dry eye, the Center for Drug Repurposing has launched a number of projects to advance knowledge about this novel treatment. These include:

  • Formulation studies
  • Stability studies
  • Mechanism of Action studies
  • Optimal dosing studies

Naltrexone is a drug originally developed in 1963 and FDA approved in 1984 as a treatment for opioid addiction. Since then, extensive research has shown that the same drug, when used at low doses (referred to as LDN or Low Dose Naltrexone) has therapeutic effects on immune related disorders and some cancers.

Following successful outcomes of patients treated with ultra-low-dose naltrexone eye drops for dry eye, the Center for Drug Repurposing has launched a number of projects to advance knowledge about this novel treatment. These include:

  • Formulation studies
  • Stability studies
  • Mechanism of Action studies
  • Optimal dosing studies

Nalmefene is an opioid antagonist developed in the early 1970’s and used primary for treating alcohol dependence. It is considered more effective than naltrexone in treating addiction due to longer half-life, greater oral absorption and no adverse effects on the liver. It also possesses some unique modes of action that different from naltrexone or other opioid antagonists.

Following successful outcomes of patients treated with ultra-low-dose nalmefene eye drops for dry eye, the Center for Drug Repurposing has launched a number of projects to advance knowledge about this novel treatment. These include:

  • Formulation studies
  • Stability studies
  • Mechanism of Action studies
  • Optimal dosing studies

 

 

To support our pioneering research for dry eye disease and thereby speed up the development of new, safe and effective treatments, please contact us by email at cdr@ariel.ac.il and we will reply with different funding opportunities. As a supporter you will benefit from early updates about our progress

 

עדכון אחרון ב-חמישי, 28 מאי 2015 11:32
 

 

ברוכים הבאים לאתר אוניברסיטת אריאל בשומרון לכל צורכי הנגישות יש ללחוץ על כפתור הנגישות למעלה